Last10K.com

Quest Diagnostics Inc (DGX) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Quest Diagnostics Inc

CIK: 1022079 Ticker: DGX
                                        



QUEST DIAGNOSTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS
    

Third quarter revenues of $1.89 billion, up 1.8% from 2017
Third quarter reported diluted EPS of $1.53, up 32.7% from 2017
Third quarter adjusted diluted EPS excluding amortization of $1.68, up 25.4% from 2017
Updates outlook for full-year 2018. Reported revenues now expected to be approximately $7.62 billion. Reported diluted EPS now expected to be between $5.57 and $5.64 and adjusted diluted EPS excluding amortization expense now expected to be between $6.53 and $6.60.

SECAUCUS, N.J., October 23, 2018 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September 30, 2018 and updated its outlook for full-year 2018.

“We grew revenues and continued to deliver strong earnings growth in the third quarter," said Steve Rusckowski, Chairman, President and CEO.  “We had a productive quarter, announcing three acquisitions and a Professional Lab Services agreement. We are updating our full-year revenue guidance to reflect lower than expected revenue performance this year, which has been affected in large part by industry headwinds we called out in the previous quarter. Looking ahead, our acquisition pipeline, along with our expanding health plan access, including UnitedHealthcare beginning January 1, position us well for growth in 2019.”

 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2018
 
2017
 
Change
 
2018
 
2017
 
Change
 
(dollars in millions, except per share data)
Reported:
 
 
 
 
 
 
 
 
 
 
 
Net revenues (a)
$
1,889

 
$
1,856

 
1.8
 %
 
$
5,692

 
$
5,537

 
2.8
 %
Diagnostic Information Services revenues (a)
$
1,810

 
$
1,777

 
1.9
 %
 
$
5,448

 
$
5,283

 
3.1
 %
Revenue per requisition
 
 
 
 
(0.8
)%
 
 
 
 
 
0.3
 %
Requisition volume
 
 
 
 
2.0
 %
 
 
 
 
 
2.3
 %
Operating income (a) (b)
$
304

 
$
298

 
1.8
 %
 
$
881

 
$
896

 
(1.7
)%
Operating income as a percentage of net revenues (a) (b)
16.1
%
 
16.1
%
 
0 bps

 
15.5
%
 
16.2
%
 
(70) bps

Net income attributable to Quest Diagnostics (b)
$
213

 
$
161

 
32.1
 %
 
$
609

 
$
518

 
17.5
 %
Diluted EPS (b)
$
1.53

 
$
1.15

 
32.7
 %
 
$
4.37

 
$
3.68

 
18.8
 %
Cash provided by operations
$
402

 
$
362

 
10.8
 %
 
$
905

 
$
852

 
6.1
 %
Capital expenditures
$
81

 
$
63

 
29.1
 %
 
$
232

 
$
170

 
36.6
 %
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted:
 
 
 
 
 
 
 
 
 
 
 
Operating income (a)
$
311

 
$
325

 
(4.2
)%
 
$
954

 
$
965

 
(1.1
)%
Operating income as a percentage of net revenues (a)
16.5
%
 
17.5
%
 
(100) bps

 
16.8
%
 
17.4
%
 
(60) bps

Net income attributable to Quest Diagnostics
$
215

 
$
174

 
23.6
 %
 
$
632

 
$
524

 
20.5
 %
Diluted EPS excluding amortization
$
1.68

 
$
1.35

 
25.4
 %
 
$
4.95

 
$
4.02

 
23.4
 %

(a)
Net revenues and selling, general and administrative expenses for the three and nine months ended September 30, 2017 have been restated to reflect the impact of new revenue recognition rules that became effective January 1, 2018 and were adopted on a retrospective basis. Under the new rules, the Company reports uncollectible balances associated with patient responsibility as a reduction in net revenues; historically these amounts were classified as bad debt expense within selling, general and administrative expenses.


1


The following information was filed by Quest Diagnostics Inc (DGX) on Tuesday, October 23, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Quest Diagnostics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Quest Diagnostics Inc.

Continue

Assess how Quest Diagnostics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Quest Diagnostics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Debt
Income
Expense
Product
Geography
Earnings
Shares
Other
Inside Quest Diagnostics Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Business Acquisitions
Business Acquisitions (Details)
Business Segment Information
Business Segment Information (Details)
Business Segment Information (Tables)
Commitments And Contingencies
Commitments And Contingencies (Details)
Debt
Debt (Details)
Description Of Business
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Fair Value Measurements
Fair Value Measurements (Narrative) (Details)
Fair Value Measurements (Recognized Assets And Liabilities At Fair Value) (Details)
Fair Value Measurements (Reconciliation Of Beginning And Ending Balances Of Assets And Liabilities Unobservable Inputs) (Details)
Fair Value Measurements (Tables)
Financial Instruments
Financial Instruments (Balance Sheets) (Details)
Financial Instruments (Income Statement) (Details)
Financial Instruments (Narrative) (Details)
Financial Instruments (Summary Of Fair Value Of Derivatives) (Details)
Financial Instruments (Summary Of Notional Amounts) (Details)
Financial Instruments (Tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Details)
Goodwill And Intangible Assets (Goodwill) (Details)
Goodwill And Intangible Assets (Tables)
Related Parties
Related Parties (Details)
Restructuring Activities
Restructuring Activities (Narrative) (Details)
Restructuring Activities (Pre-Tax Restructuring And Integration Charges) (Details)
Restructuring Activities (Tables)
Revenue Recognition
Revenue Recognition (Details)
Revenue Recognition (Tables)
Stockholders??? Equity And Redeemable Noncontrolling Interest
Stockholders??? Equity And Redeemable Noncontrolling Interest (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Details1)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies Summary Of Significant Accounting Policies (Tables)
Supplemental Cash Flow &Amp; Other Data
Supplemental Cash Flow &Amp; Other Data (Details)
Supplemental Cash Flow &Amp; Other Data (Tables)
Taxes On Income
Taxes On Income (Details)
Ticker: DGX
CIK: 1022079
Form Type: 10-Q Quarterly Report
Accession Number: 0001022079-18-000180
Submitted to the SEC: Wed Oct 24 2018 4:21:32 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Sunday, September 30, 2018
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/dgx/0001022079-18-000180.htm